Retention of contrast media in the history of radiology : Sequelae  of the former use of thorotrast and new challenges.

[Retention of contrast media in the history of radiology : Sequelae of the former use of thorotrast and new challenges]. Radiologe. 2016 Nov 24; Authors: van Kaick G, Delorme S Abstract Detection of gadolinium deposits in patients who have repeatedly been administered intravenous gadolinium chelates have given rise to concern regarding the long-term safety of magnetic resonance imaging (MRI) contrast media. Nevertheless, negative long-term clinical effects have not yet been observed. In some publications parallels have been drawn to the sequelae of thorotrast that was formerly used for arterial angiography. In this article the history of thorotrast use is briefly described and in particular why, despite warnings, this substance was used frequently and worldwide. A brief summary of the results of the German Thorotrast Study revealed that high excess rates were only observed for primary malignant liver tumors after a 15-year or longer latency period and to a lesser degree of leukemias, as well as for severe local complications due to paravascular injections, particularly in the neck region. Based on this historical review, we will venture to take stock of the outcome from the "success story" of this contrast agent. PMID: 27885402 [PubMed - as supplied by publisher]
Source: Der Radiologe - Category: Radiology Authors: Tags: Radiologe Source Type: research

Related Links:

Authors: Ducloyer JB, Ducloyer M, Tessoulin B, Lebranchu P, Deltour JB PMID: 31813551 [PubMed - as supplied by publisher]
Source: Journal Francais d Ophtalmologie - Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research
Publication date: Available online 11 December 2019Source: Life SciencesAuthor(s): Huifang Sun, Yongfa Sun, Qing Chen, Zhaoying XuAbstractAimsAcute myeloid leukemia (AML) is an aggressive cancer that invariably produces drug resistance after treatment. The aim is to explore the role of lncRNA potassium voltage-gated channel subfamily Q member 1 overlapping transcript 1 (KCNQ1OT1) and associated novel mechanisms in the progression and chemoresistance of AML.Main methodsThe expression of KCNQ1OT1, miR-193a-3p, and Tspan3 was measured by qRT-PCR. The values of IC50 for adriamycin (ADR) and the ability of proliferation were an...
Source: Life Sciences - Category: Biology Source Type: research
Publication date: Available online 11 December 2019Source: Spatial and Spatio-temporal EpidemiologyAuthor(s): Garyfallos Konstantinoudis, Dominic Schuhmacher, Håvard Rue, Ben SpycherAbstractThe main goal of disease mapping is to estimate disease risk and identify high-risk areas. Such analyses are hampered by the limited geographical resolution of the available data. Typically the available data are counts per spatial unit and the common approach is the Besag–York–Mollié (BYM) model. When precise geocodes are available, it is more natural to use Log-Gaussian Cox processes (LGCPs). In a simulation s...
Source: Spatial and Spatio-temporal Epidemiology - Category: Epidemiology Source Type: research
Condition:   Leukemia, Acute Intervention:   Drug: posaconazole oral suspensions Sponsors:   Zhujiang Hospital;   Guangdong Provincial People's Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(Children's Cancer Institute Australia) 'New therapeutic approaches are desperately needed for MLL-r leukaemia,' said Professor Richard Lock, Head of the Blood Cancers Theme at Children's Cancer Institute, Australia.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
The Theranos fiasco (see:The rise and fall of Theranos, the blood-testing startup that went from Silicon Valley darling to facing fraud charges) served to cast a pall over the micro-sample diagnostics market. Now comes news about an Israeli company with a similar strategy but this time with an instrument providing a complete blood count (CBC) and a green light from the FDA (see:Unlike Theranos, startup ’s blood test device ‘delivers on promise’ with FDA nod). Below is an excerpt from the article:Israeli startupSight Diagnostics has received US Food and Drug Administration clearance to market a blood ...
Source: Lab Soft News - Category: Laboratory Medicine Authors: Tags: AI Clinical Lab Testing Diagnostics Food and Drug Administration Healthcare Information Technology Healthcare Innovations Medical Research Point-of-Care Testing Source Type: blogs
The anti-leukemia activity of NK cells helps prevent relapse during hematopoietic stem cell transplantation (HSCT) in leukemia patients. However, the factors that determine the sensitivity or resistance of leukemia cells in the context of NK-mediated cytotoxicity are not well-established. Here, we performed a genome-wide CRISPR screen in the human chronic-myelogenous-leukemia (CML) cell line K562 to identify genes that regulate the vulnerability of leukemia cells to killing by primary human NK cells. The distribution of guide RNAs (gRNAs) in K562 cells that survived co-incubation with NK cells showed that loss of NCR3LG1, ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsThe findings of this study support the usefulness of PET/CT in the detection of subcutaneous MZL, and in staging and treatment decisions.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yilin Chen, Hua Yin, Lifeng Chen, Yingyuan Xiong, Li Meng, Jingming Guo, Haiyan Wang, Weiming LiAbstractTo investigate the real-life choice of first-line treatment in the chronic phase of chronic myeloid leukemia (CML-CP) and the feasibility of switching to nilotinib treatment strategy after first-line imatinib. We went through retrospective analysis of the efficacy and safety of imatinib versus nilotinib for first-line for CML-CP patients, and comparative analysis of the efficacy of sustained imatinib versus switchin...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: 9 December 2019Source: Cancer Cell, Volume 36, Issue 6Author(s): Andrei V. Krivtsov, Kathryn Evans, Jayant Y. Gadrey, Benjamin K. Eschle, Charlie Hatton, Hannah J. Uckelmann, Kenneth N. Ross, Florian Perner, Sarah N. Olsen, Tara Pritchard, Lisa McDermott, Connor D. Jones, Duohui Jing, Ali Braytee, Diego Chacon, Eric Earley, Brian M. McKeever, David Claremon, Andrew J. Gifford, Heather J. LeeSummaryInhibition of the Menin (MEN1) and MLL (MLL1, KMT2A) interaction is a potential therapeutic strategy for MLL-rearranged (MLL-r) leukemia. Structure-based design yielded the potent, highly selective, and orally b...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
More News: Angiography | Cancer & Oncology | History of Medicine | Leukemia | Liver | MRI Scan | Radiology | Study | Urology & Nephrology | Warnings